Adare Pharma Solutions Acquires Frontida BioPharm

BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences

February 4, 2026

Pharmaceuticals

BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

Advent International and Warburg Pincus Acquire Baxter's BioPharma Solutions to Form Simtra BioPharma Solutions

October 2, 2023

Pharmaceuticals

Advent International and Warburg Pincus completed the acquisition of Baxter International's BioPharma Solutions (BPS) business for $4.25 billion in cash, creating a standalone CDMO named Simtra BioPharma Solutions. Simtra will operate manufacturing sites in Bloomington, Indiana and Halle, Germany, establish a corporate headquarters in New Jersey, and employ approximately 1,700 people to provide sterile contract manufacturing and parenteral delivery services to pharma and biotech customers.

Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena

September 2, 2021

Healthcare Services

Ardena, a GHO Capital-backed specialist pharmaceutical CDMO, has acquired Idifarma from Suanfarma and Sodena. The deal expands Ardena's European footprint and adds Idifarma's spray drying technology and high-potency drug capabilities at its Pamplona site, supporting Ardena's integrated end-to-end CDMO strategy.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.

GHO Capital Acquires Ardena, a European Early‑Stage CDMO

January 9, 2020

Pharmaceuticals

GHO Capital Partners LLP has acquired Ardena, a Belgium‑headquartered contract development and manufacturing organisation (CDMO) focused on early‑phase drug development, from Mentha Capital and existing management. GHO will partner with Ardena's management to accelerate international growth, broaden the company’s service offering and build a fully integrated early‑stage CDMO platform through organic and inorganic expansion.

Frontage Laboratories Acquires Concord Biosciences

April 5, 2018

Healthcare Services

Frontage Laboratories Inc., a global contract research organization based in Exton, Pennsylvania, acquired Concord Biosciences (formerly Ricerca Biosciences), a preclinical CRO near Cleveland, Ohio. The acquisition adds Concord’s preclinical, toxicology, bioanalytical and agrochemical testing capabilities to Frontage’s early-stage product development services, broadening its service offering across pharmaceutical, agricultural and animal health markets.